ALLEGRA ALLERGY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Allegra Allergy, and when can generic versions of Allegra Allergy launch?
Allegra Allergy is a drug marketed by Chattem Sanofi and is included in one NDA.
The generic ingredient in ALLEGRA ALLERGY is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and four suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Allegra Allergy
A generic version of ALLEGRA ALLERGY was approved as fexofenadine hydrochloride by TEVA on September 1st, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALLEGRA ALLERGY?
- What are the global sales for ALLEGRA ALLERGY?
- What is Average Wholesale Price for ALLEGRA ALLERGY?
Summary for ALLEGRA ALLERGY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 127 |
| Clinical Trials: | 35 |
| Patent Applications: | 1,698 |
| What excipients (inactive ingredients) are in ALLEGRA ALLERGY? | ALLEGRA ALLERGY excipients list |
| DailyMed Link: | ALLEGRA ALLERGY at DailyMed |
Recent Clinical Trials for ALLEGRA ALLERGY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, San Francisco | Early Phase 1 |
| Food and Drug Administration (FDA) | Early Phase 1 |
| University of Alabama at Birmingham | Phase 2 |
Pharmacology for ALLEGRA ALLERGY
| Drug Class | Histamine-1 Receptor Antagonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for ALLEGRA ALLERGY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-007 | Jan 24, 2011 | OTC | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-010 | Jan 24, 2011 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALLEGRA ALLERGY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-010 | Jan 24, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-010 | Jan 24, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-010 | Jan 24, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-007 | Jan 24, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-007 | Jan 24, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-007 | Jan 24, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Chattem Sanofi | ALLEGRA ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 020872-007 | Jan 24, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALLEGRA ALLERGY
See the table below for patents covering ALLEGRA ALLERGY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 286641 | 4-KETO-ARALKYL CARBOXYLIC ACIDS AND ESTERS AS INTERMEDIATES | ⤷ Sign Up |
| Israel | 134770 | ⤷ Sign Up | |
| European Patent Office | 0639976 | UTILISATION DE DERIVES DE TERFENADINE EN TANT QU'ANTIHISTAMINIQUES CHEZ UN PATIENT SOUFFRANT DE TROUBLES HEPATIQUES (USE OF TERFENADINE DERIVATIVES AS ANTIHISTAMINICS IN A HEPATICALLY IMPAIRED PATIENT) | ⤷ Sign Up |
| Hungary | T76134 | ⤷ Sign Up | |
| New Zealand | 251834 | USE OF ACID DERIVATIVES OF TERFENADINE AS ANTIHISTAMINES | ⤷ Sign Up |
| Belgium | 882704 | ⤷ Sign Up | |
| Australia | 670004 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
